These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1687772)

  • 1. Calcium entry blocking, beta 1-adrenoceptor blocking and hypotensive effects of YM-16151-4.
    Shibasaki K; Uchida W; Matsuda Y; Asano M
    Arch Int Pharmacodyn Ther; 1991; 313():140-50. PubMed ID: 1687772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of YM-16151-4: a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent in rats and dogs.
    Uchida W; Shibasaki K; Matsuda Y; Asano M; Takenaka T
    J Cardiovasc Pharmacol; 1993 Aug; 22(2):247-52. PubMed ID: 7692165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profiles of YM-16151-1 and its optical isomers: a novel calcium entry blocking and selective beta-1 adrenoceptor blocking agent.
    Asano M; Uchida W; Shibasaki K; Terai M; Inagaki O; Takenaka T; Matsumoto Y; Fujikura T
    J Pharmacol Exp Ther; 1990 Jul; 254(1):204-11. PubMed ID: 1973196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of YM-16151-1 and its optical isomers: a novel calcium entry blocking and beta 1-adrenoceptor blocking agent.
    Uchida W; Shibasaki K; Asano M; Takenaka T
    Arch Int Pharmacodyn Ther; 1993; 321():30-40. PubMed ID: 8100704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effects of a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent, YM-16151-4, in anesthetized and conscious dogs.
    Uchida W; Shibasaki K; Asano M
    J Cardiovasc Pharmacol; 1992 Jan; 19(1):60-8. PubMed ID: 1375689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological properties of YM-15430-1, a 1,4-dihydropyridine derivative with beta 1-adrenoceptor-blocking activity.
    Shibasaki K; Uchida W; Shirai Y; Inagaki O; Asano M; Takenaka T
    Arch Int Pharmacodyn Ther; 1994; 328(2):213-24. PubMed ID: 7710306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vanidipinedilol: a vanilloid-based beta-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities.
    Yeh JL; Liou SF; Liang JC; Huang YC; Chiang LC; Wu JR; Lin YT; Chen IJ
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):51-63. PubMed ID: 10630733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic characterization of FR172516: a new combined calcium channel-blocking and beta-adrenoceptor-blocking agent.
    Yamamoto N; Nomura M; Okubo K; Maeda K; Goto T
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):587-94. PubMed ID: 10218729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypotensive effects of YM430, a 1,4-dihydropyridine derivative, in spontaneously hypertensive rats and renal hypertensive dogs.
    Shibasaki K; Takizawa K; Uchida W; Takenaka T
    Jpn J Pharmacol; 1997 Feb; 73(2):113-24. PubMed ID: 9074945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats.
    Honda K; Takenaka T; Shiono K; Miyata-Osawa A; Nakagawa C
    Jpn J Pharmacol; 1985 May; 38(1):31-41. PubMed ID: 2862302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antihypertensive effect of arotinolol (S-596), a new adrenergic beta blocking agent, on experimental hypertension].
    Hara Y; Nakahara H; Miyagishi A; Nakatani H
    Nihon Yakurigaku Zasshi; 1983 Aug; 82(2):103-16. PubMed ID: 6198264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive and beta-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent.
    Uchida Y; Nakamura M; Shimizu S; Shirasawa Y; Fujii M
    Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):132-49. PubMed ID: 6135395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.
    Nichols AJ; Gellai M; Ruffolo RR
    Fundam Clin Pharmacol; 1991; 5(1):25-38. PubMed ID: 1712335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenoceptor blocking properties of the stereoisomers of amosulalol (YM-09538) and the corresponding desoxy derivative (YM-11133).
    Honda K; Takenaka T; Miyata-Osawa A; Terai M
    J Pharmacol Exp Ther; 1986 Mar; 236(3):776-83. PubMed ID: 2869143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenoceptor blocking and cardiovascular effects of the optical isomers of amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent, and the corresponding desoxy derivative (YM-11133) in rats.
    Honda K; Nakagawa C; Inagaki O; Shibasaki M; Takenaka T; Takeda M
    Jpn J Pharmacol; 1986 Aug; 41(4):459-66. PubMed ID: 2877109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats.
    Shibasaki K; Uchida W; Takizawa K; Masuda N; Okazaki T; Inagaki O; Asano M; Takenaka T
    Biol Pharm Bull; 1997 Mar; 20(3):230-6. PubMed ID: 9084878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive effect of a new dihydropyridine calcium entry blocker in conscious hypertensive and normotensive rats.
    Nomura M; Kimura Y; Yoshida M; Satoh S
    Arzneimittelforschung; 1989 Dec; 39(12):1542-5. PubMed ID: 2624602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists.
    Nap A; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
    Fundam Clin Pharmacol; 2004 Jun; 18(3):309-19. PubMed ID: 15147282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive effect of the novel water-soluble calcium antagonist (+/-)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride in rats.
    Wada K; Nakamura S; Morishita S; Kanda M; Matsui H; Fukata F; Shirahase H
    Arzneimittelforschung; 1994 Oct; 44(10):1112-6. PubMed ID: 7818582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive effect of the new calcium antagonist (+-)-3-(benzylmethylamino)-2,2-dimethylpropyl-methyl-4-(2-fluoro-5- nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate hydrochloride in rats.
    Okamiya Y; Kishimoto T; Sunakawa K; Aoki K; Tanabe H; Takeshita T; Naruchi T
    Arzneimittelforschung; 1992 Jan; 42(1):9-16. PubMed ID: 1586389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.